Drug intelligence / Profile preview

BP102 + paclitaxel + carboplatin

Development stage: Unknown
Lead developer: BioMap
Modality: Small Molecules
Administration: Intravenous

Overview

BP102 + paclitaxel + carboplatin is a triple combination regimen under investigation for the first-line treatment of advanced or relapsed non-small cell lung cancer (NSCLC). BP102 is being compared directly to bevacizumab (Avastin) in combination with paclitaxel and carboplatin in a clinical trial. Paclitaxel is a microtubule-stabilizing agent that inhibits cell division, while carboplatin is an alkylating platinum compound causing DNA cross-linking and inducing apoptosis. The addition of BP102 aims to enhance the efficacy of standard paclitaxel-carboplatin regimens, though the detailed mechanism of action for BP102 itself is not published in the available search results. This combination is currently being studied for efficacy and safety in phase III clinical trials for advanced NSCLC[9].

Other names: CARBOPLATIN-TAXOLCarboTaxolPC

Targets

TUBB (Tubulin (alpha and beta subunits))DNA

Beyond the preview

Go deeper on BP102 + paclitaxel + carboplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BP102 + paclitaxel + carboplatin.

Explore the full profile